An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)
1 other identifier
observational
500
1 country
1
Brief Summary
This primary objective of this study is to describe the incidence of RSV infection in adult hematopoietic cell transplant recipients OR hematological malignancies patients in Tianjin HI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 30, 2023
CompletedFirst Submitted
Initial submission to the registry
December 6, 2023
CompletedFirst Posted
Study publicly available on registry
July 8, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2025
CompletedJuly 8, 2024
December 1, 2023
1.6 years
December 6, 2023
June 28, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
the incidence of RSV infection in adult hematopoietic stem cell transplantation (HCT) recipients OR hematological malignancies (HM) patients presenting the study site
infection incidence
1 year
the Incidence of RSV infection in adult hematopoietic stem cell transplantation (HCT) recipients OR hematological malignancies (HM) patients presenting the hospital
infection incidence
1 year
Secondary Outcomes (3)
the clinical characteristics of RSV infection
1 year
Clinical outcome and relevant risk factor of RSV infection
1 year
Virological characteristics of RSV infection from D1 through D28, D42 or even longer
1 year
Interventions
No intervention; Epidemiological Study. Participants will receive standard care based on local clinical practice
Eligibility Criteria
adult hematopoietic stem cell transplantation (HCT) recipients OR hematological malignancies (HM) patients have new onset or worsen of respiratory signs/syndromes and presented the study site.
You may qualify if:
- \) Aged ≥ 18 years old. 2) Receiving hematopoietic stem cell transplantation; OR being diagnosed with hematological malignancies (including but not limited to leukemia, lymphoma, and multiple myeloma) and receiving chemotherapy.
- \) New onset of respiratory symptoms; OR exacerbation of existing chronic respiratory symptoms (such as previously diagnosed chronic runny nose, seasonal allergies, chronic lung disease, etc.).
- \) Willing to sign an informed consent form, able to understand and willing to follow the study protocol.
You may not qualify if:
- Unwillingness to sign an informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 6, 2023
First Posted
July 8, 2024
Study Start
November 30, 2023
Primary Completion
June 20, 2025
Study Completion
June 20, 2025
Last Updated
July 8, 2024
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share